
INTERNATIONAL SEARCH REPORT

International application No. PCT/US99/24176

A. CLASSIFICATION OF SUBJECT MATTER IPC(7) :A61K 39/395; C07K 16/00; C12Q 1/00; G01N 33/53, 33/567, 33/574							
US CL :	US CL :Please See Extra Sheet.						
	o International Patent Classification (IPC) or to both	national classification and IPC					
	DS SEARCHED	11 1 25 2 2 1 1 1 2					
	ocumentation searched (classification system followed	•	_				
U.S.: 424/130.1, 152.1, 155.1; 435/4, 7.1, 7.2, 7.21, 7.23; 530/387.1, 388.2, 388.8, 388.85, 389.1, 389.7							
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched							
Electronic d	ata base consulted during the international search (na	me of data base and, where practicable,	, search terms used)				
EAST(BRS) of US Patent database, MEDLINE, BIOSIS, CAPLUS, EMBASE search terms: glypican?, syndecan?, antibod?, lectin, scfv, fab, single chain, diagnos?, prognos?, therap?, treat?							
C. DOCUMENTS CONSIDERED TO BE RELEVANT							
Category*	Citation of document, with indication, where ap	propriate, of the relevant passages	Relevant to claim No.				
x	US 5,422,243 A (JALKANEN et al) 0 13-54 and column 12- column 14.	6 June 1995, column 7, lines	1-3 and 9-11				
X,P	KLEEFF et al. The cell-surface heparan sulfate proteoglycan		1-4				
A,F	glypican-1 regulates growth factor act						
Y,P	cells and is overexpressed in human	•	9-12				
_ ,_	Invest. November, 1998, Vol. 102	-					
	especially pages 1663, second column						
	1672, first column.						
X	NACKAERTS et al. Heparan sulfate		1-4				
	human lung-cancer cells. Int. J. Car	· · · · · · · · · · · · · · · · · · ·					
Y	Vol.74, pages 335-345, especially pag	es 336, col. 1 and 341-345.	9, 10				
X Furth	er documents are listed in the continuation of Box C	. See patent family annex.					
	social categories of cited documents:	"T" later document published after the inte	emetional filing date or priority				
A doc	sument defining the general state of the art which is not considered be of particular relevance	date and not in conflict with the appl the principle or theory underlying the	ication but cited to understand				
	lier document published on or after the international filing date	"X" document of particular relevance; the considered novel or cannot be considered.	e claimed invention cannot be				
	cument which may throw doubts on priority claim(s) or which is do to establish the publication date of another citation or other	when the document is taken alone					
	cial reason (as specified)	"Y" document of particular relevance; the considered to involve an inventive					
O doc	cument referring to an oral disclosure, use, exhibition or other ans	combined with one or more other suc being obvious to a person skilled in t					
	document published prior to the international filing date but later than •&• document member of the same patent family the priority date claimed						
Date of the	actual completion of the international search	Date of mailing of the international sea	• •				
28 JANUARY 2000		11 FEB 2000					
	nailing address of the ISA/US	Authorized officer	170				
Commissioner of Patents and Trademarks Box PCT		ANNE L. HOLLERAN					
Washington, D.C. 20231 Facsimile No. (703) 305-3230		Telephone No. (703) 308-0196					
- 60031411110 17	· (/						



International application No. PCT/US99/24176

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
Oliogoi,		
K	INKI et al. Association between syndecan-1 expression and clinical outcome in squamous cell carcinoma of the head and neck. Br. J. Cancer. 1994, Vol. 70, pages 319-323, especially pages 320, 2nd column and 321-322.	1-4, 9, 10 and 12
	·	



International application No. PCT/US99/24176

A. CLASSIFICATION OF SUBJECT MATTER: US CL :					
424/130.1, 152.1, 155.1; 435/4, 7.1, 7.2, 7.21, 7.23; 530/387.1, 388.2, 388.8, 388.85, 389.1, 389.7					

Form PCT/ISA/210 (extra sheet)(July 1992)★